Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients

Launched by FUNDACIÓN EPIC · Dec 31, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients," is studying how effective and safe certain medications called parenteral antiplatelet agents are for patients undergoing a procedure known as Percutaneous Coronary Intervention (PCI) in Spain. PCI is a common treatment for heart conditions like ischemic heart disease and acute coronary syndrome, which can occur when the blood supply to the heart is blocked. The trial aims to gather information about how these medications are used in everyday practice and how they work in real-life situations.

To participate in the trial, individuals must be at least 18 years old and scheduled to undergo a PCI while receiving one of the parenteral antiplatelet agents during the procedure. However, people with certain health issues, such as active bleeding, serious blood disorders, or recent strokes, will not be eligible to participate. Those who join the study can expect to help researchers understand the short-term effects of these medications on their recovery and overall safety. This information may help improve treatment options for future patients with similar heart conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years
• • Undergoing a PCI
• • Use of a parenteral antiplatelet agent (GPIs or cangrelor)during the invasive procedure (PCI)
• Exclusion Criteria:
• • Blood dyscrasia, bleeding diathesis or active bleeding at the time of the index procedure.
• • Chronic oral anticoagulation.
• • Recent history of stroke, TIA (Transient Ischemic Attack)or intracranial bleeding (\<3 months prior to inclusion).
• • Severe anemia (Hb\<9g/dl) or platelet count \<100x106/ml at the time of the index procedure.
• • Any active neoplasm.